How should a patient with monoclonal gammopathy of undetermined significance (MGUS) characterized by an IgA kappa monoclonal protein, GM1 antibody‑associated chronic axonal sensorimotor polyneuropathy with bilateral leg weakness, radiculopathy, eosinophilic esophagitis, post‑exertional malaise, a stable enlarged liver, and a progressively enlarging spleen be treated?

Treatment Approach for IgA Kappa MGUS with Severe Neuropathy and Organomegaly

Given the severe, progressive, and disabling nature of your chronic axonal sensorimotor polyneuropathy with bilateral leg weakness, combined with a progressively enlarging spleen, you should be treated with clone-directed antimyeloma therapy, specifically a lenalidomide-based regimen as first-line treatment. 1

Rationale for Clone-Directed Therapy

Your presentation meets criteria for aggressive intervention based on European Myeloma Network guidelines 1:

• Severe and disabling neuropathy: Bilateral leg weakness with chronic axonal sensorimotor polyneuropathy represents significant functional impairment affecting quality of life and mobility
• Progressive organomegaly: The enlarging spleen suggests active disease progression, not stable MGUS
• IgA isotype with neuropathy: While the causal relationship between IgA MGUS and neuropathy is less clear than with IgM 1, the severity and progression of your symptoms warrant treatment directed at the underlying clone

The key principle is that clone-directed therapy should only be used when there is aggressive and disabling disease with a clear causal relationship between MGUS and the disorder. 1 Your constellation of progressive symptoms meets this threshold.

Specific Treatment Recommendation

Primary Treatment: Lenalidomide-Based Regimen

Lenalidomide is specifically recommended as the first choice in non-IgM MGUS-related neuropathy 1. This is superior to rituximab, which is reserved for IgM-related disease 1.

Age-Based Considerations

• If you are ≤65-70 years old: Consider high-dose melphalan with autologous stem cell transplant (autoSCT) after initial lenalidomide therapy, given the severe, progressive, and disabling nature of your symptoms 1

  • Induction therapy with lenalidomide before autoSCT may be advantageous given your poor performance status from the neuropathy and organomegaly
  • This approach is used in similarly severe conditions like POEMS syndrome 1

• If you are >70 years old: Continue with lenalidomide-based regimen without autoSCT

Critical Diagnostic Steps Before Treatment

Before initiating therapy, you must exclude progression to multiple myeloma, Waldenström macroglobulinemia, AL amyloidosis, or other lymphoproliferative disorders 1:

1. Laboratory workup:

   • Complete blood count with differential
   • Comprehensive metabolic panel (calcium, albumin, creatinine)
   • Serum and urine protein electrophoresis with immunofixation
   • Serum free light chain assay
   • Quantify M-protein level

2. Bone marrow biopsy and aspiration (mandatory for IgA MGUS) 1

3. Imaging studies:

   • Skeletal survey to exclude lytic bone lesions
   • CT or MRI to evaluate splenomegaly progression and hepatomegaly

4. Specific testing for your neuropathy:

   • Confirm GM1 antibody levels
   • Nerve conduction studies and EMG to document axonal vs demyelinating pattern
   • Consider sural nerve biopsy if diagnosis remains unclear

Important Caveats and Pitfalls

The IgA-Neuropathy Uncertainty

Critical caveat: The association between IgA MGUS and neuropathy is less established than with IgM MGUS, and the MGUS may be an incidental finding 1. However, your GM1 antibodies suggest an immune-mediated mechanism potentially related to the monoclonal protein.

Evidence Limitations

• Most neuropathy treatment data comes from IgM MGUS studies 2, 3
• Plasma exchange showed benefit primarily in IgG/IgA MGUS neuropathy in older studies 2, but this is not first-line given availability of targeted therapies
• The heterogeneous nature of IgA-associated neuropathy means treatment response is unpredictable 4

Progressive Splenomegaly as Red Flag

Your progressively enlarging spleen is particularly concerning and may indicate:

• Evolution beyond MGUS to smoldering or symptomatic myeloma
• POEMS syndrome (though you lack other typical features like endocrinopathy, sclerotic bone lesions)
• Lymphoproliferative disorder requiring different treatment

This makes the diagnostic workup absolutely mandatory before treatment initiation.

Alternative Consideration: Supportive Care Only

If diagnostic workup confirms true MGUS without progression to malignancy, and if your symptoms are deemed only mildly disabling (which seems unlikely given bilateral leg weakness), supportive care alone could be considered 1. However, your progressive splenomegaly and severe functional impairment argue strongly against watchful waiting.

Concurrent Management

While addressing the clone:

• Neuropathic pain management: Gabapentin, pregabalin, or duloxetine
• Physical therapy: Prevent contractures and maintain function
• Eosinophilic esophagitis: Continue standard EoE management (proton pump inhibitors, topical steroids, dietary modification) as this is likely unrelated to MGUS
• Post-exertional malaise: May improve with treatment of underlying clone if related to systemic inflammation

The treatment decision hinges on confirming that your neuropathy and organomegaly are truly MGUS-related rather than representing progression to overt malignancy, which would require different treatment intensity. 1, 5, 6